publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
time
move
toward
virusspecif
cell
allogen
hematopoiet
stem
cell
transplant
standard
care
abstract
adopt
immunotherapyin
particular
tcell
therapyha
recent
emerg
use
strategi
potenti
overcom
mani
limit
antivir
drug
treatment
viral
complic
hematopiet
stem
cell
transplant
review
briefli
summar
current
method
virusspecif
tcell
isol
select
report
result
clinic
trial
use
techniqu
focus
specif
strategi
aim
broaden
applic
technolog
allogen
hematopoiet
stem
cell
transplant
hsct
emerg
one
best
therapeut
option
avail
mani
patient
malign
nonmalign
diseas
involv
hematopoiet
system
use
donor
human
leukocyt
antigen
hla
match
sibl
requir
deplet
hostattack
donor
cell
prevent
graftversushost
diseas
gvhd
broader
use
altern
stem
cell
donor
sourc
unrel
donor
haploident
relat
donor
umbil
cord
blood
cb
howev
result
increas
incid
viral
infect
caus
tcell
deplet
strategi
requir
prevent
gvhd
result
infect
one
main
caus
transplantrel
mortal
morbid
set
cytomegaloviru
cmv
epsteinbarr
viru
ebv
adenoviru
adv
infect
particularli
frequent
among
hsct
recipi
often
describ
import
risk
factor
affect
prognosi
hsct
although
introduct
sensit
viral
screen
techniqu
preemptiv
treatment
strategi
reduc
death
relat
complic
current
antivir
drug
import
limit
first
depend
drug
antivir
pharmacotherapi
result
bone
marrow
suppress
substanti
toxic
difficult
manag
patient
undergon
intens
chemotherapi
radiat
second
effect
antivir
drug
exist
cmv
ebv
benefici
effect
agent
patient
adv
infect
suggest
nonrandom
uncontrol
clinic
trial
experi
often
effect
antivir
drugsespeci
use
cmvcan
lead
lateonset
cmv
diseas
antivir
pharmacotherapi
remov
lateonset
cmv
may
wors
origin
reactiv
use
agent
delay
virusspecif
immun
recoveri
result
patient
viral
complic
may
requir
multipl
treatment
cours
expens
drug
resist
may
also
occur
case
report
despit
use
antivir
drug
approxim
one
third
transplant
recipi
increas
viral
load
initi
antivir
therapi
henc
one
attract
innov
approach
overcom
limit
current
antivir
pharmacotherapi
adopt
immunotherapi
use
virusspecif
cell
past
year
increas
use
virusspecif
adopt
tcell
therapi
donorderiv
virusspecif
lymphocyt
administ
patient
primari
goal
counteract
effect
uncontrol
viral
replic
immunosuppress
patient
hsct
optim
approach
numer
vitro
studi
conduct
variou
group
attempt
identifi
best
methodolog
expans
select
virusspecif
lymphocyt
clinic
use
figur
tabl
first
experi
use
antivir
adopt
immunotherapi
use
cell
expand
cmvinfect
fibroblast
cmv
lysat
although
effect
made
difficult
export
regulatori
hurdl
requir
product
inde
expans
virusspecif
cell
often
requir
clean
room
qualiti
control
qualiti
assur
releas
test
document
meet
current
good
manfuactur
practic
cgmp
complianc
one
first
cgmpcompliant
strategi
report
manufactur
virusspecif
cell
select
virusspecif
cell
bulk
donor
lymphocyt
tetram
select
advantag
method
rapid
avail
cell
eas
select
process
requir
antigenpres
cell
apc
exogen
cytokin
extend
ex
vivo
manipul
perform
use
closedsystem
devic
outsid
dedic
clean
room
gmp
facil
howev
tetramermedi
select
select
cell
specif
singl
hlarestrict
epitop
singl
viru
case
cmv
gener
avail
donor
common
hla
type
although
sometim
effect
focus
antivir
respons
one
epitop
leav
patient
vulner
antigen
escap
observ
clinic
ebv
anoth
method
isol
virusspecif
cell
immunomagnet
select
cell
secret
interferon
ifn
g
respons
virusderiv
overlap
peptid
techniqu
advantag
cell
rapidli
avail
requir
extens
manipul
still
target
entir
antigen
virus
depend
stimuli
howev
select
unexpand
cell
associ
gvhd
tetram
technolog
option
current
avail
donor
seroposit
viru
target
anoth
gmpapplic
method
gener
virusspecif
cell
involv
stimul
peripher
blood
mononuclear
cell
pbmc
apc
approach
investig
gener
ebvspecif
cytotox
cell
ctl
stimul
pbmc
ebvtransform
lymphoblastoid
cell
line
lcl
later
modifi
includ
first
stimul
dendrit
cell
transduc
clinicalgrad
adenovir
vector
express
viral
antigen
ebv
cmv
thu
expand
antivir
specif
ctl
furthermor
ctl
expand
way
enabl
cell
recogn
three
virus
ebv
lcl
cmv
engin
adenovir
vector
adenoviru
adenovir
vector
singl
cultur
high
specif
start
rel
low
blood
volum
ml
limit
approach
timeconsum
month
requir
use
clinic
grade
viral
vector
expens
major
regulatori
hurdl
remov
need
viral
vector
recent
approach
use
dendrit
cell
either
nucleofect
plasmid
dna
encod
differ
viral
antigen
puls
overlap
peptid
viral
antigen
stimul
expand
multivirus
specif
cell
singl
stimul
total
approxim
ctl
frozen
readi
use
pend
releas
test
despit
manufactur
advanc
made
gener
virusspecif
cell
none
approach
describ
abl
expand
virusspecif
cell
donor
virusseroneg
limit
one
biggest
risk
viral
infect
exclud
immun
suppress
graft
contain
specif
tmemori
compart
cord
blood
seroneg
adult
donor
recipi
latent
infect
pathogen
peptid
interest
stimul
cell
cell
stimul
antibodi
bind
ifng
cell
allow
cell
isol
magnet
select
improv
classic
ex
vivo
expans
system
rapid
system
util
apc
present
pbmc
pbmc
puls
overlap
peptid
repres
viral
antigen
interest
apc
puls
peptid
stimul
cell
grow
coupl
grex
gasperm
cultur
devic
ctl
readi
initi
address
unmet
need
sever
group
evalu
strategi
stimul
naiv
cell
present
cord
blood
furthermor
use
grex
gasperm
devic
possibl
expand
cord
bloodederiv
cell
number
suffici
clinic
use
demonstr
first
time
possibl
gener
multivirusspecif
cell
virusinexperienc
set
cgmpapplic
manner
first
clinic
protocol
wherebi
cmvspecif
cell
cultur
hematopoiet
stem
cell
donor
transfer
recipi
success
perform
earli
seattl
group
treat
hsct
recipi
cmvspecif
clone
gener
stem
cell
donor
observ
neither
cmv
viremia
increas
cmv
diseas
attempt
rapidli
gener
cmvspecif
cell
sever
group
explor
strategi
limit
ex
vivo
expans
time
pegg
et
al
univers
colleg
london
gener
cmvspecif
cell
select
ifngesecret
cell
exposur
viral
antigen
treat
match
relat
donor
mrd
match
unrel
donor
mud
hsct
recipi
prophylaxi
preemptiv
therapi
result
trial
promis
patient
treat
prophylaxi
six
seven
patient
cmv
reactiv
cmvspecif
tcell
infus
approach
appear
less
effici
clear
ongo
infect
nine
patient
treat
preemptiv
still
requir
addit
antivir
drug
moreov
trial
gvhd
observ
multipl
patient
probabl
consequ
select
highli
activ
cell
tabl
ii
use
tetramerselect
cell
first
report
cobbold
et
al
treat
nine
patient
undergon
matchedrel
donor
mrd
match
unrel
donor
mud
hsct
cmv
reactiv
hsct
administr
tetramerselect
cmvspecif
cell
eight
nine
patient
clear
viru
two
case
gvhd
observ
data
confirm
sever
clinic
trial
show
therapi
safe
often
abl
overcom
limit
antivir
drug
feuchting
et
al
report
first
experi
advspecif
cell
use
treat
adv
infect
patient
undergo
hsct
clinic
trial
nine
patient
underw
mrd
tabl
iii
opportun
readili
activ
ebvspecif
cell
healthi
ebvseroposit
hsct
donor
use
lcl
apc
serious
infect
hsct
recipi
posttranspl
lymphoprolif
diseas
ptld
also
made
ebv
one
first
target
suitabl
adopt
immunotherapi
tabl
iv
multiinstitut
studi
enrol
patient
undergo
mrd
mud
haplohsct
none
patient
receiv
donorderiv
ebvspecif
ctl
prophylaxi
preemptiv
therapi
develop
ptld
case
de
novo
gvhd
occur
ctl
infus
histor
patient
receiv
tcelledeplet
graft
similar
condit
regimen
rate
pltd
approxim
furthermor
patient
treat
overt
ptld
achiev
complet
remiss
sustain
without
recurr
signific
advers
effect
seen
local
revers
includ
swell
site
diseas
therapeut
respons
four
patient
bulki
diseas
time
tcell
therapi
addit
group
memori
sloankett
cancer
center
report
result
anoth
larg
studi
use
ebvspecif
ctl
treatment
ptld
patient
hsct
treat
ptld
donorderiv
thirdpartyederiv
ebv
ctl
overal
respons
rate
without
evid
de
novo
recurr
gvhd
smaller
studi
report
similar
result
term
efficaci
safeti
ebvspecif
ctl
obtain
lcl
stimul
henc
adopt
transfer
ebvspecif
cell
safe
effect
strategi
prophylaxi
therapeut
set
broaden
specif
ctl
sever
group
explor
use
multivirusespecif
tcell
includ
cell
target
ebv
adv
cmv
adv
cmv
ad
ebv
one
larg
studi
australia
demonstr
efficaci
safeti
infus
bivirusespecif
cell
mrd
mud
hsct
recipi
patient
receiv
cell
specif
cmv
without
adenoviru
prophylaxi
observ
incid
gvhd
statist
signific
reduc
incid
cmv
reactiv
compar
cohort
patient
receiv
hsct
protocol
receiv
cmvspecif
cell
broaden
specif
ctl
group
baylor
colleg
medicin
expand
cell
target
cmv
ebv
adenoviru
singl
cultur
among
mrd
mud
haploident
haplo
hsct
patient
receiv
cmv
ebv
advspecif
cell
describ
eight
case
cmv
reactiv
case
adv
infect
case
ebv
reactivationptld
viral
infect
resolv
ctl
therapi
ebvand
cmvspecif
cell
detect
peripher
blood
infus
almost
patient
treat
howev
advspecif
cell
found
patient
adv
infect
importantli
howev
case
gvhd
observ
despit
fact
major
patient
recipi
altern
donor
graft
addit
cmv
ebv
adv
hsct
recipi
also
suscept
viral
infect
bk
viru
jc
viru
human
herp
viru
hhv
influenza
parainfluenza
coronaviru
human
respiratori
syncyti
viru
may
caus
sever
morbid
mortal
extend
approach
other
virus
group
baylor
colleg
medicin
describ
method
possibl
rapidli
gener
singl
prepar
polyclon
cell
specif
seven
virus
ebv
cmv
adv
bk
human
respiratori
syncyti
viru
influenza
frequent
describ
import
risk
factor
affect
prognosi
hsct
broadli
virusspecif
cell
evalu
clinic
clinicaltrialsgov
identifi
abovement
clinic
trial
one
inclus
criteria
avail
seroposit
donor
clinic
experi
tcelleadopt
immunotherapi
seroneg
donor
still
limit
cord
bloodederiv
ctl
current
test
phase
clinic
trial
nine
patient
receiv
multivirusspecif
ctl
cmv
ebv
adv
three
patient
viral
reactiv
one
patient
cmv
reactiv
adenoviru
infect
tcell
infus
increas
cmvspecif
cell
detect
peripher
blood
coincid
decreas
cmv
viral
load
patient
also
success
clear
adenoviru
infect
without
addit
antivir
therapi
two
patient
ebv
reactiv
infect
either
soon
ctl
infus
control
without
addit
therapi
coincid
detect
ebvspecif
cell
peripher
blood
widespread
use
cell
prevent
treat
viral
complic
occur
hsct
mainli
limit
rel
long
product
time
complex
product
process
limit
therapi
rel
small
number
center
sever
group
investig
differ
approach
overcom
limit
sever
strategi
emerg
potenti
suitabl
clinic
investig
alreadi
investig
ongo
studi
tetram
select
ifngesecret
tcell
isol
two
encourag
approach
term
handi
reproduc
mention
still
pitfal
emerg
approach
test
clinic
anoth
potenti
strategi
broaden
applic
virusspecif
cell
use
thirdparti
cell
gener
bank
hlatyp
virusspecif
tcell
line
readi
infus
could
repres
option
patient
suitabl
antivir
tcellebas
immunotherapi
clinic
condit
requir
prompt
intervent
tabl
v
offtheshelf
approach
initi
evalu
haqu
et
al
treat
patient
hsct
recipi
solid
organ
transplant
recipi
thirdparti
ebvspecif
ctl
ptld
observ
overal
respons
rate
week
month
case
gvhd
graft
reject
best
result
observ
patient
receiv
donor
cell
best
hlamatch
recipi
memori
sloan
ketter
group
also
confirm
safeti
strategi
describ
result
compar
use
thirdparti
ebvspecif
ctl
use
donor
lymphocyt
infus
dli
patient
develop
ptld
cb
hsct
wherea
respons
rate
similar
group
gvhd
occur
frequent
patient
treat
dli
quasim
et
al
also
describ
result
trial
enrol
patient
develop
adv
infect
mud
hsct
treat
thirdparti
advspecif
cell
highlight
high
risk
gvhd
develop
case
cell
gener
mean
ifng
captur
technolog
may
increas
risk
presenc
alloreact
cell
infus
product
final
recent
multicent
studi
use
bank
thirdparti
multivirusespecif
cell
show
feasibl
safe
approach
rapidli
treat
multipl
viral
infect
occur
hsct
studi
show
clinic
effect
possibl
even
ctl
donor
transplant
recipi
share
one
singl
hla
locu
caveat
share
allel
must
known
present
known
effect
epitop
viru
mean
extens
vitro
character
ctl
line
must
perform
laboratori
extens
expertis
nevertheless
approach
result
complet
partial
respons
rate
importantli
patient
array
hla
type
success
treat
use
cell
line
furthermor
approach
demonstr
indepth
character
ctl
product
serv
measur
potenc
also
use
custom
treatment
patient
use
bank
cell
age
antivir
immunotherapi
boutiqu
therapi
hope
come
end
sinc
first
clinic
trial
test
efficaci
cell
advanc
trend
toward
make
technolog
faster
streamlin
standard
afford
move
beyond
phase
iii
later
phase
clinic
trial
typic
sponsor
larg
pharmaceut
compani
interest
market
product
type
partnership
essenti
cell
therapi
continu
move
beyond
earlyphas
clinic
trial
academ
perspect
laboratori
must
continu
innnov
make
labori
procces
effici
cost
effect
broadli
applic
beyond
process
altern
transduct
method
transposon
overlap
peptid
must
optim
limit
use
viral
vector
final
although
thirdparti
ctl
appear
appeal
way
manufactur
ctl
administ
patient
ctl
becom
standard
care
manufactur
technolog
continu
improv
use
gasperm
cultur
devic
technolog
repres
signfici
advanc
rapid
expans
cell
devic
still
requir
multipl
manipul
expos
environ
increas
risk
contamin
must
perform
biosafeti
cabinet
largescal
cultur
bag
devic
produc
whether
support
complex
expans
requir
antigenspecif
cell
remain
test
improv
detect
techniqu
introduct
preemptiv
strategi
prognosi
patient
viral
complic
hsct
improv
pharmacotherapeut
agent
still
import
pitfal
one
investig
promis
approach
overcom
limit
antivir
drug
adopt
immunotherapi
use
virusspecif
cell
moment
differ
virusspecif
tcell
isolationgener
techniqu
avail
advantag
limit
none
shown
superior
preclin
studi
move
virusspecif
tcell
therapi
mainstream
larger
studi
necessari
simplifi
manufactur
process
extend
avail
hsct
recipi
irrespect
donor
statu
rapid
tcell
gener
thirdpartyederiv
tcell
infus
current
investig
potenti
solut
overcom
limit
regard
avail
meantim
solut
ie
ctl
gener
virusna
sourc
also
continu
test
broaden
applic
approach
author
commerci
proprietari
financi
interest
product
compani
describ
articl
